JPS56108762A - Sulfonylurea and its manufacture - Google Patents

Sulfonylurea and its manufacture

Info

Publication number
JPS56108762A
JPS56108762A JP18117980A JP18117980A JPS56108762A JP S56108762 A JPS56108762 A JP S56108762A JP 18117980 A JP18117980 A JP 18117980A JP 18117980 A JP18117980 A JP 18117980A JP S56108762 A JPS56108762 A JP S56108762A
Authority
JP
Japan
Prior art keywords
sulfonylurea
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP18117980A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0139424B2 (no
Inventor
Buaieru Ruuji
Hitsutsueru Fuorukaa
Gaizen Karuru
Regitsutsu Giyuntaa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Publication of JPS56108762A publication Critical patent/JPS56108762A/ja
Publication of JPH0139424B2 publication Critical patent/JPH0139424B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/38—2-Pyrrolones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08—Oxygen atoms
    • C07D223/10—Oxygen atoms attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP18117980A 1979-12-19 1980-12-19 Sulfonylurea and its manufacture Granted JPS56108762A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19792951135 DE2951135A1 (de) 1979-12-19 1979-12-19 Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung

Publications (2)

Publication Number Publication Date
JPS56108762A true JPS56108762A (en) 1981-08-28
JPH0139424B2 JPH0139424B2 (no) 1989-08-21

Family

ID=6088937

Family Applications (1)

Application Number Title Priority Date Filing Date
JP18117980A Granted JPS56108762A (en) 1979-12-19 1980-12-19 Sulfonylurea and its manufacture

Country Status (21)

Country Link
US (1) US4379785A (no)
EP (1) EP0031058B1 (no)
JP (1) JPS56108762A (no)
AR (3) AR231131A1 (no)
AT (1) ATE6934T1 (no)
AU (1) AU538129B2 (no)
CA (1) CA1167033A (no)
DE (2) DE2951135A1 (no)
DK (1) DK156434C (no)
ES (6) ES8200665A1 (no)
FI (1) FI75338C (no)
GR (1) GR72534B (no)
HU (1) HU184943B (no)
IE (1) IE50635B1 (no)
IL (1) IL61733A (no)
LU (1) LU90244I2 (no)
MX (4) MX6926E (no)
NL (1) NL950026I2 (no)
NO (2) NO155290C (no)
PT (1) PT72226B (no)
ZA (1) ZA807911B (no)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3134780A1 (de) * 1981-09-02 1983-03-10 Hoechst Ag, 6000 Frankfurt "sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung"
US4985417A (en) * 1989-05-02 1991-01-15 Trager Seymour F Treatment of glaucoma
JP3465247B2 (ja) * 1992-12-28 2003-11-10 アベンティス ファーマ株式会社 動脈硬化症の予防および治療剤
DE4344957A1 (de) * 1993-12-30 1995-07-06 Hoechst Ag Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe, Herstellungsverfahren und Verwendungsmöglichkeiten pharmazeutischer Präparate auf Basis dieser Verbindungen
US5631275A (en) * 1993-12-30 1997-05-20 Hoechst Aktiengesellschaft Substituted benzenesulfonylureas and -thioureas, preparation processes and possible uses of pharmaceutical preparations based on these compounds
KR100620935B1 (ko) 1998-03-19 2006-09-13 브리스톨-마이어스스퀴브컴파니 용해도가 높은 약물에 대한 2상 서방성 전달 시스템과 방법
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
IL154307A0 (en) 2000-08-07 2003-09-17 Ranbaxy Signature Llc Liquid formulation of metformin
PE20020617A1 (es) 2000-08-22 2002-08-05 Novartis Ag Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
US6806381B2 (en) * 2001-11-02 2004-10-19 Bristol-Myers Squibb Company Process for the preparation of aniline-derived thyroid receptor ligands
US7132444B2 (en) * 2002-01-07 2006-11-07 Sun Pharmaceutical Industries, Ltd. Process for the preparation of trans-3-ethyl-2,5-dihydro-4-methyl-N-[2-[4-[[[[(4-methyl cyclohexyl) amino]carbonyl]amino]sulfonyl] phenyl]ethyl]-2-oxo-1H-pyrrole-1-carboxamide
WO2004066929A2 (en) * 2003-01-24 2004-08-12 Bristol-Myers Squibb Company Cycloalkyl containing anilide ligands for the thyroid receptor
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
CZ2003530A3 (cs) * 2003-02-21 2004-07-14 Zentiva, A.S. Způsob výroby glimepiridu a příslušný meziprodukt
US7459474B2 (en) * 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
KR100712234B1 (ko) * 2003-08-08 2007-04-27 명문제약주식회사 글리메피라이드의 제조방법
CA2539384C (en) 2003-09-17 2012-08-28 Board Of Regents, The University Of Texas System Mechanism-based targeted pancreatic beta cell imaging and therapy
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
NZ547752A (en) 2003-11-12 2009-12-24 Phenomix Corp Heterocyclic boronic acid compounds for inhibiting dipeptidyl peptidase-IV
US7420059B2 (en) * 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
WO2006017292A1 (en) * 2004-07-12 2006-02-16 Phenomix Corporation Constrained cyano compounds
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
US7517991B2 (en) * 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
WO2006076598A2 (en) * 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US7368458B2 (en) * 2005-01-12 2008-05-06 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US7361766B2 (en) 2005-01-12 2008-04-22 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US7317024B2 (en) 2005-01-13 2008-01-08 Bristol-Myers Squibb Co. Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
WO2006078697A1 (en) * 2005-01-18 2006-07-27 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US7238702B2 (en) * 2005-02-10 2007-07-03 Bristol-Myers Squibb Company Dihydroquinazolinones as 5HT modulators
EP1700848A1 (en) * 2005-03-11 2006-09-13 IPCA Laboratories Limited Method for the Manufacture of Compounds Related to the Class of Substituted Sulphonyl Urea Anti-Diabetics
KR20070116778A (ko) * 2005-04-01 2007-12-11 유에스브이 리미티드 실질적으로 순수한 글리메피리드의 신규한 제조방법
UA91546C2 (uk) * 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
US7888381B2 (en) 2005-06-14 2011-02-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
TW200726765A (en) * 2005-06-17 2007-07-16 Bristol Myers Squibb Co Triazolopyridine cannabinoid receptor 1 antagonists
US7629342B2 (en) * 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US7317012B2 (en) * 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
US20060287342A1 (en) * 2005-06-17 2006-12-21 Mikkilineni Amarendra B Triazolopyrimidine heterocycles as cannabinoid receptor modulators
US7632837B2 (en) * 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7452892B2 (en) * 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
JP2009502959A (ja) * 2005-07-28 2009-01-29 ブリストル−マイヤーズ スクイブ カンパニー セロトニン受容体アゴニストおよびアンタゴニストとしての置換テトラヒドロ−１ｈ−ピリド［４，３，ｂ］インドール
US7795436B2 (en) * 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
US8618115B2 (en) 2005-10-26 2013-12-31 Bristol-Myers Squibb Company Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7553836B2 (en) * 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
US20070238770A1 (en) * 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
CN101092402B (zh) * 2006-06-23 2012-02-08 唐仲雄 磺酰脲类化合物及其医药用途
US7968577B2 (en) 2006-11-01 2011-06-28 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
WO2008057857A1 (en) 2006-11-01 2008-05-15 Bristol-Myers Squibb Company MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
ES2393885T7 (es) 2007-06-04 2014-01-30 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US20090011994A1 (en) * 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
US20090076125A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched glimepiride
EP2209780B1 (en) 2007-11-01 2014-01-01 Bristol-Myers Squibb Company Nonsteroidal compounds useful as modulators of glucocorticoid receptor ap-1 and/or nf- kappa b activity and use thereof
PE20091928A1 (es) * 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
AU2010212867B2 (en) 2009-02-13 2013-05-16 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a SGLT2 inhibitor, a DPP-IV inhibitor and optionally a further antidiabetic agent and uses thereof
EA024072B1 (ru) * 2009-02-13 2016-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Фармацевтическая дозированная форма, включающая производное глюкопиранозилдифенилметана, и применения для улучшения гликемического контроля у пациентов
CN102448456A (zh) 2009-03-27 2012-05-09 百时美施贵宝公司 用dpp-iv抑制剂预防重度有害心血管事件的方法
KR20120036850A (ko) 2009-05-15 2012-04-18 노파르티스 아게 알도스테론 신타제 억제제로서의 벤족사졸론 유도체
PL2429995T3 (pl) 2009-05-15 2014-07-31 Novartis Ag Arylopirydyny jako inhibitory syntazy aldosteronu
KR20120041702A (ko) 2009-05-28 2012-05-02 노파르티스 아게 네프릴리신 억제제로서의 치환된 아미노부티르산 유도체
CN103896796B (zh) 2009-05-28 2016-04-27 诺华股份有限公司 作为脑啡肽酶抑制剂的取代的氨基丙酸衍生物
KR101813025B1 (ko) 2009-09-30 2017-12-28 베링거 인겔하임 인터내셔날 게엠베하 글루코피라노실­치환된 벤질­벤젠 유도체의 제조방법
NZ598318A (en) 2009-09-30 2014-02-28 Boehringer Ingelheim Int Method for the preparation of a crystalline form of 1-chloro-4- (beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
ES2663351T3 (es) 2009-11-17 2018-04-12 Novartis Ag Derivados de aril-piridina como inhibidores de la aldosterona sintasa
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
US8575160B2 (en) 2009-11-30 2013-11-05 Novartis Ag Imidazole derivatives as aldosterone synthase inhibitors
EP2590634B1 (en) 2010-07-09 2016-03-09 BHV Pharma, Inc. Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
TR201101809A1 (tr) 2010-12-21 2012-07-23 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Vildagliptin ve glimepirid kombinasyonları.
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
IN2014CN04119A (no) 2011-11-15 2015-07-10 Reddys Lab Ltd Dr
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2014039411A1 (en) 2012-09-05 2014-03-13 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists
EP2892897A1 (en) 2012-09-05 2015-07-15 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
US9486433B2 (en) 2012-10-12 2016-11-08 Mochida Pharmaceuticals Co. Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
PL2956464T3 (pl) 2013-02-14 2018-08-31 Novartis Ag Podstawione pochodne bisfenylowe kwasu butanowofosfonowego jako inhibitory nep (neutralnej endopeptydazy)
AU2014230444B2 (en) 2013-03-15 2018-05-17 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
PT2981271T (pt) 2013-04-05 2019-02-19 Boehringer Ingelheim Int Utilizações terapêuticas de empagliflozina
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN105377266A (zh) 2013-04-18 2016-03-02 勃林格殷格翰国际有限公司 药物组合物、治疗方法及其用途
RS65632B1 (sr) 2013-06-05 2024-07-31 Bausch Health Ireland Ltd Ultra-prečišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i upotrebe
CN103288703B (zh) * 2013-06-09 2015-10-21 南通市华峰化工有限责任公司 Ⅱ型糖尿病药物格列美脲中间体苯磺酰胺的合成方法
CN103420891B (zh) * 2013-06-09 2015-10-21 南通市华峰化工有限责任公司 Ⅱ型糖尿病药物格列美脲中间体苯磺胺三光气的合成方法
CA2918077A1 (en) 2013-07-25 2015-01-29 Novartis Ag Bioconjugates of synthetic apelin polypeptides
BR112016001542A2 (pt) 2013-07-25 2017-08-29 Novartis Ag Polipeptídios cíclicos para o tratamento de insuficiência cardíaca
US9593113B2 (en) 2013-08-22 2017-03-14 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
US20170239276A1 (en) 2014-09-05 2017-08-24 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical combinations of sitagliptin
EP3009422A1 (en) * 2014-10-14 2016-04-20 Ludwig-Maximilians-Universität München Photo-switchable sulfonylureas and their uses
CR20170338A (es) 2015-01-23 2017-09-12 Novartis Ag Conjugados de ácidos grasos y apelina sintética con mayor vida media
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
CN108383768A (zh) * 2018-04-13 2018-08-10 江西博雅欣和制药有限公司 一种格列美脲原料药合成工艺
CN112028807A (zh) * 2020-08-07 2020-12-04 重庆康刻尔制药股份有限公司 一种格列美脲原料药的精制方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4945066A (no) * 1972-08-07 1974-04-27

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670700U (de) 1952-11-12 1954-01-21 Siemens Ag Aufhaengevorrichtung fuer pendelleuchten.
DE1198354B (de) * 1963-09-25 1965-08-12 Hoechst Ag Verfahren zur Herstellung von Benzol-sulfonylharnstoffen
LU47776A1 (no) * 1964-07-30 1966-07-13
DE1445774A1 (de) * 1964-07-30 1969-01-23 Hoechst Ag Verfahren zur Herstellung von Benzolsulfonylharnstoffen
DE1443911C3 (de) * 1964-12-08 1974-12-05 Farbwerke Hoechst Ag, Vormals Meister Lucius & Bruening, 6000 Frankfurt Benzolsulfonylharnstoffe, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate
DE1670700B2 (de) * 1966-05-14 1978-06-22 Hoechst Ag, 6000 Frankfurt Benzolsulfonylharnstoffe, Verfahren zu ihrer Herstellung und deren Verwendung
US3646009A (en) * 1967-03-15 1972-02-29 Boehringer & Soehne Gmbh Anti-diabetically active sulfonyl-semicarbazides
US3819633A (en) * 1970-04-01 1974-06-25 Erba Carlo Spa (iso)quinolyl sulfonylureas having antidiabetic activity
DE2103118A1 (en) * 1971-01-23 1972-08-24 Farbwerke Hoechst AG, vormals Meister Lucius & Brüning, 6000 Frankfurt 4 (2-heterocyclylethyl) - benzenesulphonylureas - with hypoglycaemic activity
US3962244A (en) * 1971-01-23 1976-06-08 Hoechst Aktiengesellschaft Benzene sulfonyl ureas
DE2621958A1 (de) * 1976-05-18 1977-12-08 Hoechst Ag Benzolsulfonylharnstoffe und verfahren zu ihrer herstellung
MTP848B (en) * 1978-06-27 1980-06-24 Hoechst Ag Sulfonyl ureas process for their manufacture pharmaceutical preparation on the basis of there compounds and their use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4945066A (no) * 1972-08-07 1974-04-27

Also Published As

Publication number Publication date
JPH0139424B2 (no) 1989-08-21
AR240922A2 (es) 1991-03-27
AR231131A1 (es) 1984-09-28
ES8202541A1 (es) 1982-02-01
IL61733A0 (en) 1981-01-30
MX8254A (es) 1993-04-01
NO803855L (no) 1981-06-22
FI75338C (fi) 1988-06-09
AR240922A1 (es) 1991-03-27
AR230989A1 (es) 1984-08-31
ES498227A0 (es) 1982-02-01
EP0031058A1 (de) 1981-07-01
ES8202542A1 (es) 1982-02-01
AU538129B2 (en) 1984-08-02
MX174496B (es) 1994-05-19
NO155290B (no) 1986-12-01
ES8202543A1 (es) 1982-02-01
IL61733A (en) 1985-05-31
MX8352A (es) 1993-11-01
PT72226B (de) 1982-03-26
ES498228A0 (es) 1982-02-01
FI75338B (fi) 1988-02-29
FI803937L (fi) 1981-06-20
ATE6934T1 (de) 1984-04-15
NL950026I2 (nl) 1997-01-06
PT72226A (de) 1981-01-01
CA1167033A (en) 1984-05-08
NO1996009I1 (no) 1996-07-30
DK156434C (da) 1990-01-22
IE50635B1 (en) 1986-05-28
ES497661A0 (es) 1981-11-01
ES8202798A1 (es) 1982-03-01
DK156434B (da) 1989-08-21
DE3067390D1 (en) 1984-05-10
ES498225A0 (es) 1982-03-01
GR72534B (no) 1983-11-17
DE2951135A1 (de) 1981-06-25
ES498224A0 (es) 1982-02-01
DK540280A (da) 1981-06-20
NL950026I1 (no) 1996-01-02
HU184943B (en) 1984-11-28
ES8200665A1 (es) 1981-11-01
MX6926E (es) 1986-12-01
AU6552380A (en) 1981-06-25
ES498226A0 (es) 1982-03-01
US4379785A (en) 1983-04-12
NO155290C (no) 1987-03-11
ZA807911B (en) 1981-12-30
IE802676L (en) 1981-06-19
ES8202799A1 (es) 1982-03-01
EP0031058B1 (de) 1984-04-04
LU90244I2 (fr) 1998-07-20

Similar Documents

Publication Publication Date Title
JPS56108762A (en) Sulfonylurea and its manufacture
JPS5695331A (en) Ferroofluid and its manufacture
JPS55100368A (en) Nnbenzylimidazole and its manufacture and use
PH18683A (en) Novel 4-aroylimidazol-2-ones and their use
JPS5612370A (en) Substituted 33aryllpyrazole and 33aryllisoxazole and manufacture thereof
JPS5632427A (en) Novel 44fluoroo33phenoxyybenzaldehydeacetal* its manufacture* novel intermediate therefor and its manufacture
JPS5690086A (en) 11piperidinesulfonylurea and its manufacture
JPS55154979A (en) Novel 33vinylcephalosporin and its manufacture
JPS56124651A (en) Lockerrhousing and lockerrcover
JPS5617245A (en) Long structure and its manufacture
JPS5640680A (en) 33methyleneflavanone and 33methylenechromanone and their use
JPS55154994A (en) Amtibiotic aa6888c and aa6888x
JPS5690094A (en) Hydantoinylsilane and its manufacture
JPS5626862A (en) Novel substituted phenylacetylguanidine and its manufacture
JPS55120627A (en) Novel complex and its manufacture
JPS5688861A (en) Construction and its manufacture
JPS565479A (en) Novel 33substituteddtetrahydropyrrolopyrimidines and their manufacture
JPS55124768A (en) Phenylmorphanes*its intermediate and its manufacture
JPS5634655A (en) 33methyllcyclohexadecc33enee11one* its manufacture and use
JPS55151571A (en) Novel 22isopropylaminoo55halogenopyrimidine and its manufacture
JPS5616441A (en) 44fluoroo33bromoobenzoylfluoride and manufacture thereof
JPS55130950A (en) Betaaalkoxyyacrylonitrile*33aminooacryonitrile and 22cyanoovinylester manufacture
JPS5634656A (en) Cyclopentadecc88enee11one* its manufacture and its use
JPS5659740A (en) N*nndimethylln**isobutyllnnbetaa hydroxyethylpropylenediamine and its manufacture
JPS5616435A (en) 33methylaldehyde* its manufacture and use

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term